Navigation Links
Green tea may negate the effects of a common cancer therapy
Date:2/3/2009

(WASHINGTON, February 3, 2009) Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer. However, a new study suggests that some components of green tea may counteract the anticancer effects of one cancer therapy, bortezomib (Velcade), and may be contraindicated for patients taking this medicine to ensure its maximum therapeutic benefit. This study is being prepublished online today in Blood, the official journal of the American Society of Hematology.

Because of its increasing popularity and availability to the public in many formulations, green tea has been increasingly studied to understand its effect on cancer, heart disease, and other conditions. In animal studies, an antioxidant compound in green tea called the EGCG polyphenol (epigallocatechin gallate) has been shown to be a potent anticancer agent, with effects demonstrated against leukemia, as well as lung, prostate, colon, and breast cancer. Among other properties, EGCG binds to a common protein in tumors called GRP78 (which is responsible for preventing cell death) and inhibits its function, thereby assisting in the death of tumor cells.

We know that cancer patients look to green tea extracts among other natural supplements to complement their therapeutic regimens. We wanted to better understand how the compounds in green tea interact with a cytotoxic chemical therapy and how that may affect patient outcomes, said Axel Schnthal, PhD, of the University of Southern California Keck School of Medicine and senior study author.

In this study, researchers evaluated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, a blood cancer, and glioblastoma, a malignant brain tumor. Bortezomib, an anticancer therapy approved to treat multiple myeloma and mantle cell lymphoma, normally fights disease by inhibiting proteasomes and inducing tumor cell death. However, in both in vitro and in vivo mouse experiments, the team was surprised to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteasome inhibitory function the two compounds effectively contradicted one another in the cell, leaving nearly 100 percent of the tumor cells intact.

Importantly, the team found that EGCG only reacted with proteasome inhibitors that have a boronic acid base (including bortezomib) but did not react with several non-boronic acid-based proteasome inhibitors (such as nelfinavir [Viracept], a treatment for HIV). The researchers determined that the boronic acid in bortezomib helped to bind the EGCG directly to the therapy molecule, thereby cancelling out the effects of both the green tea and the therapy on the tumor cells.

The study findings may have several important implications in the clinical setting. The EGCG blocked bortezomibs antitumor effects at levels that are commonly achieved with the use of available concentrated green tea supplements (as low as 2.5 μM which can be attained with two to three 250 mg capsules of green tea extract) suggesting the impact is very real for patients supplementing their therapy. The team also believes that as the EGCG inactivates bortezomibs function in the tumor cell, it may also prevent some of the side effects that usually accompany the therapy. As a result, patients taking green tea products to supplement their therapy may experience improved well being and feel encouraged to increase their intake while unknowingly blunting or completely negating the efficacy of their bortezomib treatment.

Our surprising results indicate that green tea polyphenols may have the potential to negate the therapeutic efficacy of bortezomib, said Dr. Schnthal. The current evidence is sufficient enough to strongly urge patients undergoing bortezomib therapy to abstain from consuming green tea products, in particular the widely available, highly concentrated green tea and EGCG products that are sold in liquid or capsule form.

The findings of the study are considered specific for patients taking bortezomib as opposed to any other common cancer therapy. The analysis of the study offered a clear understanding of the boronic acid-related mechanisms that cause the negative outcome, offering the conclusion that green tea would counteract most, if not all, compounds that work with boronic acid. However, while there are many chemicals that contain boronic acid, few are being used with patients.

Although the study has exposed detrimental effects of green tea in specific combination with Velcade, this should not minimize the previously reported potentially beneficial effect of this herb, said Dr. Schnthal. Related studies with other types of cancer therapies are promising and green tea extract may actually improve the anticancer effects of other drugs.


'/>"/>

Contact: Patrick C. Irelan
pirelan@hematology.org
202-292-0253
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. USC study finds that green tea blocks benefits of cancer drug
2. Green Tea May Negate the Effects of a Common Cancer Therapy
3. Milkscreen Home Test for Alcohol in Breast Milk Begins Nationwide Sales at Walgreens
4. Recent U.S. Ambassador to Tanzania Mark Green Named Managing Director of Malaria No More Policy Center
5. Healthcare Sector Leaders Urge Obama, Congress to Invest in Alternative Energy and Green Jobs in Healthcare
6. DSM Joins the American Chemical Society Green Chemistry Institute(R)s Pharmaceutical Roundtable
7. Waking Up And Getting Ready: New Green Guide Advocates Simple Living and Earth-Centered Spirituality
8. CMS Data Services Reports Record Response to Data Media "GREEN" Repurchase Program
9. My1Stop.com Partners with Green Business Alliance to Help Customers Go Green
10. Chicago's First Eco-friendly, Green Luxury Dental Practice - ORA Dental Studio - is Finally Here
11. Greenland's National Management of Health Partners with AMD Global Telemedicine Inc. and AFHCAN to Install Telemedicine Encounter Management Systems (TEMS) Across Greenland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot this ... of professional staff discussed strategies for preventing outbreaks among camp communities during the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
(Date:3/27/2017)... ... 27, 2017 , ... The respected dental team at Northwood ... without the extensive time commitment and aesthetic disadvantages of traditional braces can now ... custom-designed series of virtually invisible aligners are created for each patient and crafted ...
(Date:3/27/2017)... Plains, NY (PRWEB) , ... March 27, 2017 , ... ... Root Canal Awareness Week by teaching their patients about the key role this treatment ... therapy from an experienced endodontist. To better serve those who need a root ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... 2017 Summary This report ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
Breaking Medicine Technology: